Quetiapine Fumarate

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Borderline Personality Disorder

Conditions

Borderline Personality Disorder

Trial Timeline

May 1, 2005 → May 1, 2008

NCT ID

NCT00122070

About Quetiapine Fumarate

Quetiapine Fumarate is a phase 3 stage product being developed by AstraZeneca for Borderline Personality Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00122070. Target conditions include Borderline Personality Disorder.

What happened to similar drugs?

0 of 3 similar drugs in Borderline Personality Disorder were approved

Approved (0) Terminated (0) Active (3)

🔄Olanzapine + placeboEli LillyPhase 3

🔄OlanzapineEli LillyPhase 3

🔄quetiapine extended-release + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00498628	Phase 2	Completed	Dec 1, 2007	Mar 1, 2010	Alcoholism
NCT00370500	Approved	Completed	Apr 1, 2007	Jul 1, 2008	Schizophrenia
NCT00326105	Phase 3	Completed	Apr 1, 2006	Jul 1, 2007	Major Depressive Disorder
NCT00326144	Phase 3	Completed	Apr 1, 2006	May 1, 2007	Major Depressive Disorder
NCT00329264	Phase 3	Completed	Apr 1, 2006	Aug 1, 2007	Generalized Anxiety Disorder
NCT00320268	Phase 3	Completed	Apr 1, 2006	May 1, 2007	Major Depressive Disorder
NCT00122070	Phase 3	Completed	May 1, 2005	May 1, 2008	Borderline Personality Disorder
NCT00314184	Phase 3	Completed	Mar 1, 2005	Jul 1, 2007	Bipolar Disorder
NCT00227305	Phase 3	Completed	Aug 1, 2004	Dec 1, 2007	Schizophrenia
NCT00304473	Phase 3	Completed	Aug 1, 2004	Apr 1, 2006	Schizophrenia
NCT00090311	Phase 3	Completed	Jul 1, 2004	Jul 1, 2006	Bipolar Disorder
NCT00085891	Phase 3	Completed	Jun 1, 2004	Sep 1, 2005	Schizophrenia
NCT00083954	Phase 3	Completed	Jun 1, 2004	Aug 1, 2005	Bipolar Disorder
NCT00449397	Phase 3	Completed	Jul 1, 2003	Jan 1, 2006	Psychosis

Competing Products

12 competing products in Borderline Personality Disorder

See all competitors

Product	Company	Stage	Hype Score
Olanzapine + placebo	Eli Lilly	Phase 3	40
olanzapine	Eli Lilly	Pre-clinical	26
Olanzapine	Eli Lilly	Phase 3	40
Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab + Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate	Jiangsu Hengrui Medicine	Phase 2	31
Durvalumab + Tremelimumab + Gemcitabine + Cisplatin	AstraZeneca	Phase 2	27
quetiapine extended-release + Placebo	AstraZeneca	Phase 3	40
Quetiapine fumarate + Placebo	AstraZeneca	Phase 2	35
ziprasidone + Placebo	Pfizer	Phase 2	35
Fluorouracil + Irinotecan + Irinotecan Hydrochloride + Leucovorin + Leucovorin Calcium + Nivolumab + Oxaliplatin	Bristol Myers Squibb	Phase 1	29
PD-1/PD-L1 inhibitors + Chemotherapy	BeOne Medicines	Phase 2	36
Fluorouracil + Irinotecan + Leucovorin + Leucovorin Calcium + Oxaliplatin + Quemliclustat + Zimberelimab	Arcus Biosciences	Phase 1/2	33
vafidemstat + Placebo	Oryzon Genomics	Phase 2	25